Anorexia nervosa (AN) is a disorder characterized by abnormal eating behavior, weight regulation, and disturbances in attitudes and perceptions toward body weight and shape. Although progress has been made in the treatment of AN, a substantial portion of patients have a limited response to treatment. Multiple endocrine and metabolic changes occur after prolonged starvation, conserving energy and protein. A number of the endocrine findings in patients with AN may be secondary to adaptive mechanisms. However, AN differs from simple starvation in that excess of both feeding-stimulatory (orexigenic) and feeding-inhibitory (anorexigenic) signalling is characteristic, producing the 'mixed' signal about satiety and desire to feed. This leads to a failure of the adaptive feeding response that is initiated by a decrease in leptin, an adiposity signal from fat tissue, and the resultant increase and decrease of orexigenic and anorexigenic signalling, respectively. The hypothesis of unbalanced shift of feeding-regulatory circuitry places anorexigenic corticotropin-releasing factor and orexigenic neuropeptide Y in the final common neurobiological substrate for AN. Therapeutic intervention using such receptor antagonists may lead to more successful and targeted psychopharmacological treatment. Molecular Psychiatry (2001) 6, 620-624.
Anorexia nervosa (AN) and bulimia nervosa (BN) are disorders of unknown origin that most commonly occur in women (about 3% over their lifetimes) and usually have their onset in adolescence. These illnesses have become a major focus of attention in terms of both the research community and the general public. [1] [2] [3] [4] [5] Patients with eating disorders invariably have a disturbed body image and an intense fear of weight gain. Although endocrine disturbances such as those in pituitary -adrenal, -thyroid, and -gonadal axes are common in AN and BN, it is more a consequence of starvation than a cause of their eating disorder psychopathology. Little is known about the etiology and the intrinsic biological alterations. Although pathological eating behavior has tended to be viewed as derivative and not the primary pathophysiology, recent development in the understanding of feeding and body weight regulation has shed new light on the role of feeding regulators in the systematic disturbance of the structure of feeding behavior in AN patients. [6] [7] [8] [9] [10] [11] [12] [13] [14] Correspondence: Dr A Inui, Associate Professor, Second Department of Internal Medicine, Kobe University School of Medicine, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan. E-mail: inuiȰmed.kobe-u.ac.jp 
Hypothalamic response to starvation
The concept of the adipostat was originally proposed as a model for the regulation of food intake, and it was posited that the amount of energy stored in the form of adipose tissue could be detected and held constant by the central nervous system. Leptin, a 16-kDa protein secreted by adipocytes in proportion to body fat, was found to be a critical element of this system ( Figure 1) . 15 Leptin acts via cell surface receptors in the hypothalamus, the effects of which are mediated by a growing list of hypothalamic regulators on feeding, including orexigenic signals such as neuropeptide Y (NPY), as well as anorexigenic signals such as corticotropin-releasing factor (CRF). 11, 12, 14, 16 Leptin appears to play an important role in triggering an adaptive response to starvation since weight loss causes leptin levels to fall in proportion to the loss of body fat mass. Low leptin levels in the brain increase the activity of the orexigenic signals that stimulate eating and suppress energy expenditure, and decrease the activity of the anorexigenic signals that cause anorexia and weight loss (Figure 1a ). NPY is a neurotransmitter that is widely expressed throughout the brain. NPY pathways from the arcuate to the paraventricular nuclei of the hypothalamus are known to be activated in response to fasting, as well as in other conditions associated with negative energy balance such as caloric restriction, lactation, intense exercise, and uncontrolled diabetes. 11, 12, 16 NPY consists of an intercon- Figure 1 A simplified model of the hypothalamic feeding-regulatory circuitry in response to starvation (a) and in anorexia nervosa (b). Leptin acts as part of a feedback loop to maintain constant stores of fat. This is achieved by hypothalamic effector molecules downstream of leptin that regulate food intake and energy expenditure. Loss of body fat (starvation) leads to a decrease in leptin, which in turn leads to a state of positive energy balance wherein food intake exceeds energy expenditure. This compensatory response is mediated by increased production, release, and/or action of neuropeptide Y (NPY) and other orexigenic neuropeptides, as well as a decreased activity of anorexigenic signals such as corticotropin-releasing factor (CRF). In anorexia nervosa, simultaneous excess of orexigenic and anorexigenic signalling may produce a 'mixed' signal, leading to a failure of this adaptive feeding response. An increase in leptin or serotonergic function during or after the recovery may cause the patients difficulty in achieving and sustaining normal weight. Relative decrease in anorexigenic signalling such as cholecystokinin (CCK) and pancreatic polypeptide (PP) may underlie the occurrence and/or the maintenance of bulimic binging behavior. Anorexics and bulimics appear to have different disturbances in feeding-regulatory signals, such as increased and decreased CCK in the plasma [22] [23] [24] and decreased and normal homovanillic acid, a major metabolite of dopamine in the cerebrospinal fluid, 33 respectively. These may suggest different neurobiological bases between the two subtypes. There are reports of other potential signals such as growth hormone releasing hormone and thyrotropin releasing hormone that might have a role in the altered appetite regulation in AN. 34 Positive and negative regulators of food intake and body adiposity are expressed as red and blue, respectively, with the caliber of the arrows being proportionate to the impact. Abbreviations: +, stimulatory input; −, inhibitory input; AGRP, agouti-related protein; CART, cocaine-and amphetamine-regulated transcript; GLP-1, glucagon-like peptide I 7-36 amide; IL-6, interleukin-6; MCH, melanin-concentrating hormone; TNF-␣, tumor necrosis factor-alpha.
nected orexigenic network that includes galanin, opioid peptides, melanin-concentrating hormone (MCH), orexin, and agouti-related protein (AGRP). Most of these peptides are up-regulated in ob/ob mice that lack functional leptin, and their expressions are increased through fasting, suggesting an important role of these orexigenic signals in facilitating the recovery of lost weight. 11, 12, 16 The persistence of body weight loss in AN, therefore, implies a failure of this adaptive feeding response, but this has only been thought to be due to a relentless and successful pursuit of thinness by the patients.
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Abnormalities in feeding regulators in anorexia nervosa
The possible etiologic role of biological factors has been difficult to study because good animal models do not yet exist. Therefore, altered appetite or satiety signals that may contribute to the development and/or the maintenance of AN have been investigated by measuring a range of feeding regulators in the blood or the cerebrospinal fluid (CSF) of the patients.
1,2 Limited data suggest that AN patients have disturbances of certain orexigenic and anorexigenic signals in the brain and the periphery (Figure 1b) .
Anorexigenic signals
Malnourished and underweight AN patients have consistently been found to have significantly reduced plasma and CSF leptin concentrations compared to normal weight controls, suggesting a normal physiological response to starvation. 17, 18 However, an elevated CSF to plasma leptin ratio was observed in AN patients, and CSF leptin concentrations reached normal values before full weight restoration during feeding, possibly as a consequence of the relatively rapid and disproportionate accumulation of fat during refeeding. These findings suggest an implication in the difficulty in achieving and sustaining a normal weight in AN. 17 Plasma leptin levels may be decreased in normal weight bulimics, and the eating pattern may play a role in the modulation of leptin secretion. Insulin levels may also be relatively increased in AN because of hypercortisolemia, which has been linked to the control of food intake and to the regulation of body weight.
12,19 CRF is a major anorexigenic signal in the hypothalamus. In addition to its role as controller of the hypothalamic-pituitary-adrenal axis, CRF inhibits food intake, increases energy expenditure, and produces sustained weight loss. 9, 11, 12 Several studies have reported elevated CRF levels in the CSF of underweight anorexics, indicating an implication for anorexia and weight loss, as well as for the accompanied neuroendocrine disturbance. 20 The neurotransmitter serotonin is involved in the physiological system relevant to AN. 7, 21 Increase in brain serotonin function leads to reduction in food intake in both animals and humans. CSF levels of the major serotonin metabolite, 5-hydroxyindoleacetic acid (5-HIAA), are low in underweight AN but rise to above normal levels in individuals who have made long-standing recoveries. 21 This suggests that a premorbid disturbance in serotonergic function may be a risk factor for the development of AN. Cholecystokinin (CCK), a hormone released from the intestine after eating, is known to be involved in the control of short-term satiety in many species, including man. Increased and decreased CCK responses to meals were reported in patients with AN and those with BN, respectively. [22] [23] [24] Pancreatic polypeptide (PP), a hormone released from the pancreas after eating, is also thought to be a circulating satiety factor in both humans and rodents.
14 Basal as well as stimulated PP secretion is exaggerated in AN, and the presence of bulimic symptoms is associated with reduced PP and CCK responsiveness. 24 Tumor necrosis factor-␣ (TNF-␣), also known as cachectin, is a cytokine that mediates weight loss in experimental animals and humans. 13 Chronic TNF exposure causes cachexia characterized by anorexia, weight loss and depletion of whole-body protein and lipid. Plasma concentrations of TNF-␣ and its soluble receptor were significantly higher in anorectic patients than in controls, and these remained altered even after weight restoration. 25 Most of these feeding inhibitory signals are known to inhibit the NPY orexigenic network. 11, 12, 14, 16 
Orexigenic signals
Underweight anorexics had significantly elevated concentrations of CSF NPY compared to normal controls. 18 ,26 NPY levels are not normalized until a long time after the weight has normalized and frequently at the same time as the resumption of menstruation. CSF concentrations of PYY, a powerful feeding stimulator structurally related to NPY, were significantly elevated in bulimic women studied after a month of abstinence from binging and vomiting compared to controls and patients with AN. It was suggested from animal experiments that abnormally elevated CNS PYY activity in the abstinent state may contribute to a persistent drive in feeding behavior, particularly a desire for sweet foods and the resumption of binging behavior.
1,2 BN patients had normal CSF NPY levels in contrast to AN. A radioreceptor assay, which can measure overall opioid activity, showed that underweight anorexics had an increase of CSF opioid activity.
1,2 However, CSF concentrations of ␤-endorphin and dynorphin, some of the endogenous opioid peptides, as well as those of galanin, were not increased in underweight anorexics, suggesting an inhibitory influence from anorexigenic signals or masking of the abnormality by the contributions of other brain areas to the total CSF immunoreactivity.
Hypothesis
Few methods are available at present to assess CNS activity of orexigenic and anorexigenic signals in humans and to identify the specific pathways that may underlie the altered expression of the signals.
1,2 However, the data described here allow us to formulate a hypothesis for the role of feeding regulators in the development and/or the maintenance of the pathological feeding behavior in AN. Even though most of the disturbances may not be permanent features and thus not trait-related disturbances, they are strongly entrenched and are not easily corrected by improved nutrition or short-term weight normalization. 1, 2 The arcuate NPY neurons are in a strategic position to monitor the metabolic state of animals and are activated normally in a state of negative energy balance. 9, 11, 12 NPY is a component of hypothalamic circuitry integrating aspects of feeding behavior and energy homeostasis. The NPY orexigenic network is composed of signals such as opioids and galanin, as well as the newly identified MCH, orexin, and AGRP. In anorectic patients, the compensatory increase in orexigenic signals is observed but is compromised by the simultaneous excess of anorexigenic signalling such as CRF, CCK, PP, and TNF-␣, indicating dysregulation of hypothalamic feeding-regulatory circuitry. Although information is needed on newly identified orexigenic and anorexigenic signals, this may explain why many anorexics cannot easily reverse their illness in contrast to simple starvation. It is possible that the 'mixed' signal about satiety and desire to feed could contribute to the ambivalence about food, ie, the dis-sociation that anorexics often display between reduced caloric intake and obsessive thoughts about food. An imbalance between orexigenic and anorexigenic signalling may underlie the occurrence of bulimic binging behavior in which a relative, but not absolute, decrease in anorexigenic signals such as CCK and PP may be characteristic. 24 It is another postulate that the alterations in feeding-regulatory circuitry play a role in the obsessional preoccupation with body weight and body shape, an aversively conditioned learning. NPY was reported to produce taste aversion at the same doses that stimulate appetite and influence memory retention in rodents. 27 Hypersecretion of vasopressin and reduced CSF oxytocin in underweight AN patients may also maintain or exacerbate the persistent preoccupation with the adverse consequences of feeding. 
Testing the hypothesis
Research over the past few years has provided an unprecedented expansion of our knowledge about the molecular mechanisms regulating body fat. Although much of this knowledge has come from studies of obesity, there appear to be implications for clinical conditions associated with weight loss. 9, 13 There is a large effort to develop new modulators of monoamine neurotransmitters and neuropeptide receptor agonists or antagonists that have been associated with food intake and energy expenditure, some of which are presently being evaluated in clinical trials for obesity. 28 It warrants evaluation in the treatment of AN or BN. Specifically, antagonists for the CRF 2 receptor that mediate feeding inhibition by CRF are expected to be effective for restricting AN if produced, and antagonists for Y 1 and Y 5 receptors that mediate feeding stimulation by NPY and PYY, for a permanent drive in feeding behavior, particularly the resumption of binging behavior. These neuropeptides appear to be the final common neurobiological substates for AN although there is increasing evidence that normally a dynamic equilibrium exists between NPY and CRF neuronal activity (Figure 1) . Application of CRF antagonists is especially of theoretical interest since intracerebroventricular administration of CRF to experimental animals produces many of the physiologic and behavioral changes classically associated with AN, including decreased feeding behavior, hyperactivity, hypothalamic hypogonadism, decreased sexual activity, and decreased gastric emptying. 1, 2, [6] [7] [8] [9] 12, 13, 29, 30 Since the final integration of food intake control is brought about by maintenance of a delicate balance between orexigenic and anorexigenic signals, it is necessary to correct for such unbalanced shift in feeding-regulatory circuitry as much as possible. However, we should keep in mind that the hypothesis is mostly based on the measurement of CSF or plasma concentrations of the signals, which will give us rather limited information on their activity in the feeding-regulatory center of the brain. It is known that enhanced release of both norepinephrine and dopamine in the lateral hypothalamus is associated with the inhibition of food intake, but in the Molecular Psychiatry medial hypothalamic nuclei is associated with the stimulation of food intake in experimental animals. 31 Therefore, in order to establish a causal relationship, the purported factors would need to be manipulated and shown to have an effect on the development or course of the illness. A battery of psychological testing would be useful to evaluate a patient's attitude toward food as well as other behavioral alterations. 29 Although selective serotonin reuptake inhibitors significantly reduced relapse and improved the outcome when given after weight restoration, 32 this may be due to reduction in obsession, compulsion, and other associated psychological disturbances by the compound.
Current treatments for AN are aimed at normalizing body weight, correcting the irrational preoccupation with weight loss, and preventing relapse. [3] [4] [5] Many individuals who develop AN during adolescence and young adulthood eventually make full recoveries. However, for at least 50% of these patients, the longterm outcome is not as good. Many individuals remain irrationally concerned about weight gain and never achieve a normal body weight. The mortality, due to complications of starvation or from suicide, is substantial, apporoximately 5% per decade of follow-up. 4 It is expected that correction of the abnormalities in feeding-regulatory circuitry improves not only pathological eating behaviors but also associated cognition and mood alterations, leading to a better prognosis.
Advances in molecular genetics may permit the identification of genes that predispose individuals to develop AN or BN. Although polymorphisms in genes of the serotonin (S-HT) system such as the 5-HT 2A receptor and susceptibility to AN need to be further clarified, greater knowledge of the biological factors in the development and maintenance of the pathology will lead to innovative approaches to treatment and prevention.
